Assessment of Thyroid Function in Patients With Alkaptonuria.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
02 03 2020
Historique:
entrez: 24 3 2020
pubmed: 24 3 2020
medline: 12 9 2020
Statut: epublish

Résumé

Alkaptonuria is an autosomal recessive disorder caused by pathogenic variants in the HGD gene. Deficiency of the HGD enzyme leads to tissue deposition of homogentisic acid (HGA), causing severe osteoarthropathies and cardiac valve degeneration. Although HGD is vital for the catabolism of tyrosine, which provides the basis for thyroid hormone synthesis, the prevalence of thyroid dysfunction in alkaptonuria is unknown. To assess thyroid structure and function in patients with alkaptonuria. A single-center cohort study was conducted in a tertiary referral center including patients with alkaptonuria followed up for a median of 93 (interquartile range, 48-150) months between February 1, 2000, and December 31, 2018. The alkaptonuria diagnosis was based on clinical presentation and elevated urine HGA levels. A total of 130 patients were considered for participation. Prevalence of thyroid dysfunction in adults with alkaptonuria compared with the general population. Thyrotropin and free thyroxine levels were measured by immunoassay and repeated in each patient a median of 3 (interquartile range, 2-22) times. Neck ultrasonographic scans were analyzed in a subset of participants. Logistic regression was used to test the association of thyroid dysfunction with age, sex, thyroid peroxidase (TPO) antibodies, serum tyrosine levels, and urine HGA levels. Of the 130 patients, 5 were excluded owing to thyroidectomy as the cause of hypothyroidism. The study cohort consisted of 125 patients; the median age was 45 (interquartile range, 35-51) years. Most of the patients were men (72 [57.6%]). The prevalence of primary hyperthyroidism was 0.8% (1 of 125 patients), similar to 0.5% observed in the general population (difference, 0.003; 95% CI, -0.001 to 0.04; P = .88). The prevalence of primary hypothyroidism was 16.0% (20 of 125 patients), which is significantly higher than 3.7% reported in the general population (difference, 0.12; 95% CI, 0.10-0.24; P < .001). Women were more likely to have primary hypothyroidism than men (odds ratio, 10.99; 95% CI, 3.13-38.66; P < .001). Patients with TPO antibodies had a higher likelihood of primary hypothyroidism than those without TPO antibodies (odds ratio, 7.36; 95% CI, 1.89-28.62; P = .004). There was no significant difference in the prevalence of thyroid nodules between patients in this study (29 of 49 [59.2%]) vs the general population (68%) (difference, 0.088; 95% CI, -0.44 to 0.73; P = .20) or of cancer (7% vs 5%; difference, 0.01; 95% CI, -0.01 to 0.17; P = .86). The high prevalence of primary hypothyroidism noted in patients with alkaptonuria in this study suggests that serial screening in this population should be considered and prioritized.

Identifiants

pubmed: 32202644
pii: 2763227
doi: 10.1001/jamanetworkopen.2020.1357
pmc: PMC7090965
doi:

Substances chimiques

Autoantibodies 0
Autoantigens 0
Iron-Binding Proteins 0
Tyrosine 42HK56048U
Thyrotropin 9002-71-5
TPO protein, human EC 1.11.1.7
Iodide Peroxidase EC 1.11.1.8
Homogentisic Acid NP8UE6VF08
Thyroxine Q51BO43MG4

Types de publication

Evaluation Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e201357

Commentaires et corrections

Type : CommentIn

Références

Pediatr Endocrinol Diabetes Metab. 2016;22(2):71-75
pubmed: 28329776
Rare Dis. 2013 Dec 18;1:e27475
pubmed: 25003018
N Engl J Med. 2002 Dec 26;347(26):2111-21
pubmed: 12501223
Lancet. 2017 Sep 23;390(10101):1550-1562
pubmed: 28336049
Arch Intern Med. 2000 Feb 28;160(4):526-34
pubmed: 10695693
AANA J. 2005 Feb;73(1):41-6
pubmed: 15727283
Endocr Pract. 2012 Nov-Dec;18(6):988-1028
pubmed: 23246686
Thyroid. 2007 Dec;17(12):1211-23
pubmed: 18177256
Am J Hum Genet. 1998 Sep;63(3):920-1
pubmed: 9718357
Thyroid. 2016 Oct;26(10):1343-1421
pubmed: 27521067
Rheumatol Int. 2005 Mar;25(2):81-5
pubmed: 15322814
J Cardiothorac Vasc Anesth. 2009 Aug;23(4):586-8
pubmed: 18948036
Orthopedics. 2014 Dec;37(12):e1141-9
pubmed: 25437092
JIMD Rep. 2015;24:51-66
pubmed: 26093627
J Anaesthesiol Clin Pharmacol. 2011 Apr;27(2):259-61
pubmed: 21772695
Mol Genet Metab. 2011 Aug;103(4):307-14
pubmed: 21620748
Clin Endocrinol (Oxf). 2015 Sep;83(3):412-9
pubmed: 25308831
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Endocrinol Invest. 1994 Dec;17(11):837-42
pubmed: 7745231
Clin Genet. 2003 Feb;63(2):145-9
pubmed: 12630963

Auteurs

Shirisha Avadhanula (S)

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.

Wendy J Introne (WJ)

National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.

Sungyoung Auh (S)

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.

Steven J Soldin (SJ)

Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland.

Brian Stolze (B)

National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.

Debra Regier (D)

Children's National Rare Disease Institute, Children's National Medical Center, Washington, DC.

Carla Ciccone (C)

National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.

Fady Hannah-Shmouni (F)

National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.

Armando C Filie (AC)

National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Kenneth D Burman (KD)

Endocrine Section, Medstar Washington Hospital Center, Washington, DC.

Joanna Klubo-Gwiezdzinska (J)

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH